<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83912">
  <stage>Registered</stage>
  <submitdate>11/05/2009</submitdate>
  <approvaldate>27/05/2009</approvaldate>
  <actrnumber>ACTRN12609000374268</actrnumber>
  <trial_identification>
    <studytitle>The safety and efficacy of a locally available probiotic in premature infants.</studytitle>
    <scientifictitle>A randomised placebo controlled pilot trial on the safety and efficacy of a probiotic product in reducing all case mortality and definite necrotizing enterocolitis in preterm very low birthweight neonates.</scientifictitle>
    <utrn />
    <trialacronym>PANTS</trialacronym>
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Necrotising Enterocolitis</healthcondition>
    <healthcondition>all cause mortality and time to full feeds in preterm very low birthweight neonates</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a prospective double blind placebo controlled randomised trial investigating the safety and efficacy of a locally available probiotic product. 
Enrolled neonates will be allocated to the product (containing Lactobacillus acidophilus 375 million, Bifidobacterium bifidum &amp; Bifidobacterium longus 125 million organisms) or an identical looking placebo containing maltodextrin.
This is available in tablet form, which is crushed and mixed with 3ml of sterile water at the bedside, and given twice daily by mouth / gastric tube, from the start of enteral feeds until discharged home or term (37 weeks post menstral age) whichever comes first.</interventions>
    <comparator>The placebo will appear identical to the probiotic and consist of maltodextrin.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Gut colonisation by probiotic bacteria assessed by quantitative stool culture</outcome>
      <timepoint>one sample collected before commencing supplement and then another sample colleced after four weeks of supplement (probiotic or placebo)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality</outcome>
      <timepoint>During first admission after birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stage II Necrotising Enterocolitis (NEC) or greater (Bell Staging)</outcome>
      <timepoint>At death or discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Late onset sepsis (blood culture positive after 72 hrs of life)</outcome>
      <timepoint>At death or discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to reach full feeds (150 ml/kg/day)</outcome>
      <timepoint>At death or discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1)Gestation up to 32 weeks and 6 days 
(2)Birth weight under 1500 grams
(3)Ready to commence or on enteral feeds for up to 12 hours
(4)  Parental Consent</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>32</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1) Major congenital malformation 
(2) Chromosomal aberration 
(3) Lack of informed parental consent 
(4) On enteral feeds for more than 12 hours 
(5) Contraindications for enteral feds
 (6) Life threatening illness/condition</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After obtaining informed parental consent, babies will be allocated to study supplement (product or placebo) from computer generated random numbers concealed in sealed, coded opaque envelopes.</concealment>
    <sequence>Sequence generation will be by computer generated random numbers.
Randomisation will be stratified by gestation up to 27weeks + 6days and above 28weeks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>15/06/2009</anticipatedstartdate>
    <actualstartdate>7/12/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>21/05/2012</actualenddate>
    <samplesize>120</samplesize>
    <actualsamplesize>159</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Womens and Childrens Health Service</primarysponsorname>
    <primarysponsoraddress>King Edward Memorial Hospital
374 Bagot Rd
Subiaco 
Perth WA 6008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Telethon</fundingname>
      <fundingaddress>POBox 50
Tuart Hill Perth 
Western Australia 6939</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof Sanjay Patole</sponsorname>
      <sponsoraddress>Neonatal Paediatrics
King Edward Memorial Hospital 
374 Bagot Rd
Subiaco 
Perth WA 6008</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a two stage project:
 (1) independent microbiological studies to confirm the identity of the probiotic bacteria and the safety (contaminants, unspecified contents, osmolarity) of the probiotic product followed by 
(2) a pilot clinical trial to test the hypothesis that routine supplementation with this probiotic product will result in colonisation of the gut (primary hypothesis) and reduction in all cause deaths, and diseases like NEC, and late onset sepsis (secondary hypotheses) in premature babies.</summary>
    <trialwebsite />
    <publication> Patole S, Keil AD, Chang A, Nathan E, Doherty D, Simmer K, Esvaran M, Conway
P. Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria 
in preterm neonates--a randomised double blind placebo controlled trial. PLoS
One. 2014 Mar 3;9(3):e89511. doi: 10.1371/journal.pone.0089511. eCollection 2014.
PubMed PMID: 24594833; PubMed Central PMCID: PMC3940439.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>King Edward Memorial Hospital Committee</ethicname>
      <ethicaddress>King Edward Memorial Hospital
374 Bagot Rd
Subiaco 
Perth WA 6008</ethicaddress>
      <ethicapprovaldate>7/04/2009</ethicapprovaldate>
      <hrec>1649/EW</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Prof Sanjay Patole</name>
      <address>Neonatal Paediatrics
King Edward Memorial Hospital 
374 Bagot Rd
Subiaco 
Perth WA 6008</address>
      <phone>+61 8 9340 1260</phone>
      <fax />
      <email>sanjay.patole@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Prof Sanjay Patole</name>
      <address>Neonatal Paediatrics
King Edward Memorial Hospital 
374 Bagot Rd
Subiaco 
Perth WA 6008</address>
      <phone>+61 8 9340 1260</phone>
      <fax />
      <email>sanjay.patole@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Prof Sanjay Patole</name>
      <address>Neonatal Paediatrics King Edward Memorial Hospital 374 Bagot Rd Subiaco Perth WA 6008</address>
      <phone>+61 8 9340 1260</phone>
      <fax />
      <email>sanjay.patole@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Patole Sanjay</name>
      <address>Department of neonatal paediatrics, KEM Hospital for Women, 374 Bagot Road, Subiaco, Perth, western Australia 6008</address>
      <phone>61-8-93401260</phone>
      <fax />
      <email>sanjay.patole@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>